Zymeworks Inc Stock, NYSE:ZYME
114 East 4th Avenue, Suite 800, Vancouver, British Columbia V5T 1G4
Number of Employees: 458
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.